Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia
A Phase I Study of Arry-520 and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma
Sponsor: M.D. Anderson Cancer Center
A PHASE1 clinical study on Plasma Cell Leukemia and Recurrent Plasma Cell Myeloma, this trial is completed. The trial is conducted by M.D. Anderson Cancer Center and has accumulated 13 data snapshots since 2012. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Aug 2019 — Jan 2021 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Apr 2019 — Aug 2019 [monthly]
Active Not Recruiting PHASE1
▶ Show 8 earlier versions
-
Dec 2018 — Apr 2019 [monthly]
Active Not Recruiting PHASE1
-
Nov 2018 — Dec 2018 [monthly]
Active Not Recruiting PHASE1
-
Oct 2018 — Nov 2018 [monthly]
Active Not Recruiting PHASE1
-
Jul 2018 — Oct 2018 [monthly]
Active Not Recruiting PHASE1
-
Jun 2018 — Jul 2018 [monthly]
Active Not Recruiting PHASE1
-
Dec 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE1
-
Feb 2017 — Dec 2017 [monthly]
Active Not Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1
First recorded
Feb 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- M.D. Anderson Cancer Center
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .